These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 33533182

  • 1. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
    Takamori S, Matsubara T, Fujishita T, Ito K, Toyozawa R, Seto T, Yamaguchi M, Okamoto T.
    Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
    [Abstract] [Full Text] [Related]

  • 2. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
    Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X.
    N Engl J Med; 2020 Sep 03; 383(10):931-943. PubMed ID: 32469185
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
    Roth KG, Mambetsariev I, Salgia R.
    Cold Spring Harb Mol Case Stud; 2020 Dec 03; 6(6):. PubMed ID: 33335011
    [Abstract] [Full Text] [Related]

  • 5. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
    Tanaka H, Taima K, Makiguchi T, Nakagawa J, Niioka T, Tasaka S.
    Cancer Commun (Lond); 2021 Jan 03; 41(1):83-87. PubMed ID: 33387444
    [Abstract] [Full Text] [Related]

  • 6. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, Dingemans AMC, Lolkema MP, Paats MS, Dubbink HJ.
    Lung Cancer; 2020 Feb 03; 140():46-54. PubMed ID: 31862577
    [Abstract] [Full Text] [Related]

  • 7. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Mathieu LN, Larkins E, Akinboro O, Roy P, Amatya AK, Fiero MH, Mishra-Kalyani PS, Helms WS, Myers CE, Skinner AM, Aungst S, Jin R, Zhao H, Xia H, Zirkelbach JF, Bi Y, Li Y, Liu J, Grimstein M, Zhang X, Woods S, Reece K, Abukhdeir AM, Ghosh S, Philip R, Tang S, Goldberg KB, Pazdur R, Beaver JA, Singh H.
    Clin Cancer Res; 2022 Jan 15; 28(2):249-254. PubMed ID: 34344795
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
    Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, Delmonte A, Sini C, Galetta D, Roca E, Pelizzari G, Cortinovis D, Gariazzo E, Pilotto S, Citarella F, Bria E, Muscolino P, Pozzessere D, Carta A, Pignataro D, Calvetti L, Leone F, Banini M, Di Micco C, Baldini E, Favaretto A, Malapelle U, Novello S, Pasello G, Tiseo M.
    ESMO Open; 2024 Sep 15; 9(9):103680. PubMed ID: 39214048
    [Abstract] [Full Text] [Related]

  • 10. Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.
    Takamori S, Seto T, Yamaguchi M, Kinoshita F, Fujishita T, Ito K, Toyozawa R, Shoji F, Okamoto T.
    Front Oncol; 2022 Sep 15; 12():965741. PubMed ID: 36313664
    [Abstract] [Full Text] [Related]

  • 11. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
    Wu ZX, Li J, Dong S, Lin L, Zou C, Chen ZS.
    Drugs Today (Barc); 2021 Apr 15; 57(4):265-275. PubMed ID: 33851690
    [Abstract] [Full Text] [Related]

  • 12. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW, Chang JW, Wu CE.
    Int J Mol Sci; 2022 Oct 05; 23(19):. PubMed ID: 36233109
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV.
    J Hematol Oncol; 2021 Aug 23; 14(1):129. PubMed ID: 34425853
    [Abstract] [Full Text] [Related]

  • 14. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
    Blanc-Durand F, Alameddine R, Iafrate AJ, Tran-Thanh D, Lo YC, Blais N, Routy B, Tehfé M, Leduc C, Romeo P, Stephenson P, Florescu M.
    Oncologist; 2020 Nov 23; 25(11):916-920. PubMed ID: 32716573
    [Abstract] [Full Text] [Related]

  • 15. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC, INSIGHT Investigators.
    Lancet Respir Med; 2020 Nov 23; 8(11):1132-1143. PubMed ID: 32479794
    [Abstract] [Full Text] [Related]

  • 16. Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
    Friese-Hamim M, Clark A, Perrin D, Crowley L, Reusch C, Bogatyrova O, Zhang H, Crandall T, Lin J, Ma J, Bachner D, Schmidt J, Schaefer M, Stroh C.
    Lung Cancer; 2022 Jan 23; 163():77-86. PubMed ID: 34942492
    [Abstract] [Full Text] [Related]

  • 17. Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.
    Kunimasa K, Kawamura T, Tamiya M, Inoue T, Kuhara H, Nishino K, Kumagai T.
    Thorac Cancer; 2021 Dec 23; 12(24):3426-3428. PubMed ID: 34695875
    [Abstract] [Full Text] [Related]

  • 18. Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape.
    Simard MA, Cabrera-Galvez C, Viteri S, Geist F, Reischmann N, Zühlsdorf M, Karachaliou N.
    Neoplasia; 2024 Nov 23; 57():101063. PubMed ID: 39366215
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
    Shitara K, Yamazaki K, Tsushima T, Naito T, Matsubara N, Watanabe M, Sarholz B, Johne A, Doi T.
    Jpn J Clin Oncol; 2020 Aug 04; 50(8):859-866. PubMed ID: 32328660
    [Abstract] [Full Text] [Related]

  • 20. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
    Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R.
    Cancer Chemother Pharmacol; 2022 Jul 04; 90(1):53-69. PubMed ID: 35771259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.